243 related articles for article (PubMed ID: 31648711)
1. Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass.
Pireaux V; Tassignon J; Demoulin S; Derochette S; Borenstein N; Ente A; Fiette L; Douxfils J; Lancellotti P; Guyaux M; Godfroid E
J Am Coll Cardiol; 2019 Oct; 74(17):2178-2189. PubMed ID: 31648711
[TBL] [Abstract][Full Text] [Related]
2. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.
Decrem Y; Rath G; Blasioli V; Cauchie P; Robert S; Beaufays J; Frère JM; Feron O; Dogné JM; Dessy C; Vanhamme L; Godfroid E
J Exp Med; 2009 Oct; 206(11):2381-95. PubMed ID: 19808248
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection.
Demoulin S; Godfroid E; Hermans C
J Thromb Haemost; 2021 Feb; 19(2):323-329. PubMed ID: 33047454
[TBL] [Abstract][Full Text] [Related]
4. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.
Larsson M; Rayzman V; Nolte MW; Nickel KF; Björkqvist J; Jämsä A; Hardy MP; Fries M; Schmidbauer S; Hedenqvist P; Broomé M; Pragst I; Dickneite G; Wilson MJ; Nash AD; Panousis C; Renné T
Sci Transl Med; 2014 Feb; 6(222):222ra17. PubMed ID: 24500405
[TBL] [Abstract][Full Text] [Related]
5. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
Koster A; Fischer T; Gruendel M; Mappes A; Kuebler WM; Bauer M; Kuppe H
J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
[TBL] [Abstract][Full Text] [Related]
6. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
Al-Horani RA; Abdelfadiel EI; Afosah DK; Morla S; Sistla JC; Mohammed B; Martin EJ; Sakagami M; Brophy DF; Desai UR
J Thromb Haemost; 2019 Dec; 17(12):2110-2122. PubMed ID: 31397071
[TBL] [Abstract][Full Text] [Related]
7. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.
Xu Y; Cai TQ; Castriota G; Zhou Y; Hoos L; Jochnowitz N; Loewrigkeit C; Cook JA; Wickham A; Metzger JM; Ogletree ML; Seiffert DA; Chen Z
Thromb Haemost; 2014 Apr; 111(4):694-704. PubMed ID: 24336918
[TBL] [Abstract][Full Text] [Related]
8. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
[TBL] [Abstract][Full Text] [Related]
9. FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis.
May F; Krupka J; Fries M; Thielmann I; Pragst I; Weimer T; Panousis C; Nieswandt B; Stoll G; Dickneite G; Schulte S; Nolte MW
Br J Haematol; 2016 Jun; 173(5):769-78. PubMed ID: 27018425
[TBL] [Abstract][Full Text] [Related]
10. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
[TBL] [Abstract][Full Text] [Related]
11. Management of refractory bleeding post-cardiopulmonary bypass in an acute heparin-induced thrombocytopenia type II renal failure patient who underwent urgent cardiac surgery with bivalirudin (Angiox
Hassen K; Maccaroni MR; Sabry H; Mukherjee S; Serumadar S; Birdi I
Perfusion; 2018 Apr; 33(3):235-240. PubMed ID: 28789610
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
13. Are Ticks the Answer to Medical Device-Associated Clotting?
Weitz JI; Chan NC
J Am Coll Cardiol; 2019 Oct; 74(17):2190-2192. PubMed ID: 31648712
[No Abstract] [Full Text] [Related]
14. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
15. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
Harrington J; Piccini JP; Alexander JH; Granger CB; Patel MR
J Am Coll Cardiol; 2023 Feb; 81(8):771-779. PubMed ID: 36813377
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons.
Bel A; Borik W; Davidson S; Helies JM; Stimmer L; Fremes S; Zelenkofske S; Rusconi C; Alexander J; Alexander D; Menasché P; Pepper J
Eur J Cardiothorac Surg; 2016 Feb; 49(2):682-9. PubMed ID: 25953802
[TBL] [Abstract][Full Text] [Related]
17. Factor XI as a Therapeutic Target.
Gailani D; Gruber A
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1316-22. PubMed ID: 27174099
[TBL] [Abstract][Full Text] [Related]
18. Monitoring and management of anticoagulation in children requiring extracorporeal circulation.
Malviya S
Semin Thromb Hemost; 1997; 23(6):563-7. PubMed ID: 9469631
[TBL] [Abstract][Full Text] [Related]
19. Hemostatic-endothelial interactions: a potential anticoagulant role of the endothelium in the pulmonary circulation during cardiac surgery.
Cardigan RA; Mackie IJ; Machin SJ
J Cardiothorac Vasc Anesth; 1997 May; 11(3):329-36. PubMed ID: 9161902
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation management during cross-clamping and bypass.
Lander H; Zammert M; FitzGerald D
Best Pract Res Clin Anaesthesiol; 2016 Sep; 30(3):359-70. PubMed ID: 27650345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
